ANI Pharmaceuticals Files 8-K on Financials
Ticker: ANIP · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
ANI Pharma dropped an 8-K on Aug 6th covering financials - check it out.
AI Summary
ANI Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The company, incorporated in Delaware, is headquartered at 210 Main Street West, Baudette, Minnesota.
Why It Matters
This filing provides crucial updates on ANI Pharmaceuticals' financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information.
Key Players & Entities
- ANI Pharmaceuticals, Inc. (company) — Registrant
- August 6, 2024 (date) — Date of Report
- 210 Main Street West, Baudette, Minnesota (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific financial information is detailed in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the header.
When was the earliest event reported in this filing?
The earliest event reported was on August 6, 2024.
What is ANI Pharmaceuticals, Inc.'s primary business classification?
ANI Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Has ANI Pharmaceuticals, Inc. operated under any previous names?
Yes, the company previously operated as BIOSANTE PHARMACEUTICALS INC until December 28, 1999, and before that as BEN ABRAHAM TECHNOLOGIES INC until October 27, 1999.
Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-08-06 06:53:07
Filing Documents
- ani-20240806.htm (8-K) — 28KB
- anip-20240806xexx991.htm (EX-99.1) — 353KB
- a1.jpg (GRAPHIC) — 5KB
- 0001023024-24-000083.txt ( ) — 535KB
- ani-20240806.xsd (EX-101.SCH) — 2KB
- ani-20240806_lab.xml (EX-101.LAB) — 21KB
- ani-20240806_pre.xml (EX-101.PRE) — 12KB
- ani-20240806_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 6, 2024, ANI Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.*
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 6 , 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 6, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer